Trials / Terminated
TerminatedNCT03383146
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo injected subcutaneously twice daily. |
| DRUG | Relamorelin | Relamorelin 10 μg injected subcutaneously twice daily. |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2020-11-05
- Completion
- 2020-11-05
- First posted
- 2017-12-26
- Last updated
- 2021-11-23
- Results posted
- 2021-11-23
Locations
349 sites across 27 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, Germany, Hungary, India, Israel, Latvia, Malaysia, Mexico, Philippines, Poland, Russia, Singapore, South Africa, South Korea, Spain, Thailand, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03383146. Inclusion in this directory is not an endorsement.